MK-0524A (niacin/laropiprant) tablet
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for MK-0524A (niacin/laropiprant) tablet, covering 2014-03-14 to 2014-03-14. Get the full timeline:
Most recent: Clinical Trial Update: Niacin/Laropiprant Tablet for South and Southeast Asians With Low High-Density Lipoprotein Cholesterol (LDL-C) at Risk for Cardiovascular Disease (MK-0524A-108) [Phase 3]